# A Study to Evaluate the Renal Protective Effect (Urine Albumin-to-Creatinine Ratio (UACR)), Efficacy and Safety of Ipragliflozin in Type 2 Diabetes Mellitus Patients With Albuminuria

> **NCT03118713** · PHASE4 · TERMINATED · sponsor: **Astellas Pharma Korea, Inc.** · enrollment: 33 (actual)

## Conditions studied

- Type 2 Diabetes Mellitus

## Interventions

- **DRUG:** metformin
- **DRUG:** ipragliflozin
- **DRUG:** glimepiride

## Key facts

- **NCT ID:** NCT03118713
- **Lead sponsor:** Astellas Pharma Korea, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2017-04-25
- **Primary completion:** 2018-12-12
- **Final completion:** 2018-12-12
- **Target enrollment:** 33 (ACTUAL)
- **Why stopped:** Business decision due to enrollment challenges
- **Last updated:** 2024-11-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03118713

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03118713, "A Study to Evaluate the Renal Protective Effect (Urine Albumin-to-Creatinine Ratio (UACR)), Efficacy and Safety of Ipragliflozin in Type 2 Diabetes Mellitus Patients With Albuminuria". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03118713. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*